2023年4月22日

|綜合分析和主要趨勢全球激素替代療法市場需求預期達到7.1%到2032年的120億美元。激素替代療法(HRT)主要是用來緩解絕經後症狀。荷爾蒙替代療法替代方法更年期女性的荷爾蒙,是低水平的。更年期期間,幾個女人經曆痛苦的症狀,比如陰道幹澀和潮熱。激素治療或更年期荷爾蒙療法,被認為是一種有效的治療選擇更年期症狀,平衡體內的荷爾蒙水平。由於這些因素,荷爾蒙替代療法的需求預計將增加在預測期間。此外,對激素替代療法的需求增加而越來越多的人意識到相關的生物藥物治療癌症。生物製劑和蛋白質產品的市場開發了由於創新分析觀察過去二十年。得到樣本報告+相關圖表& Charts@ https://www.futuremarketinsights.com/reports/sample/rep - gb - 3871這是由於允許深入物理化學的先進分析技術比較複雜的蛋白質分子和蛋白質藥物。這反過來有助於研發新的藥物和治療。 As per FMI, the market presents high growth opportunities in emerging countries such as China and India. Emerging countries are focused upon improving their healthcare infrastructure due to increasing resources and large patient pool in these regions. In addition, necessary medications are imported from developed regions due to the lack of several manufacturers in developing regions, which increases their cost. Hence, key players are expanding their manufacturing capacity to generate revenue from hormone replacement therapy. Key Takeaways from Market Study By therapy type, the estrogen replacement therapy segment is expected to hold over 37.8% market value share by the end of 2032. By dosage form, oral tablets/capsules segment is leading with over 41.4% of market share by 2032. By indication, menopause segment will exhibit robust growth at a CAGR of 5.4% over the assessment period. By end-user, hospitals held the highest segment share in terms of the market share value of 55.3% in 2021. North America is considered the leading region with a value share of 30.1% by the end of the forecast period, owing to the presence of larger number of CROs and CMOs in the U.S. “With increasing prevalence of autoimmune disorders and expenditure to accelerate R&D activities, the hormone replacement therapy market is expected to witness advancements over the forecast period,” says an analyst of Future Market Insights. To remain ‘ahead’ of your competitors, Ask a Question@ https://www.futuremarketinsights.com/ask-question/rep-gb-3871 Market Competition Companies are adopting strategies such as mergers and acquisitions to gain competitive edge. Leading manufacturers such as Eli Lilly and Company, AbbVie, and Endo International plc are also adopting these strategies to enhance their presence in the market For instance: In July 2021, Eli Lilly and Company acquired Protomer Technologies to identify and synthesize molecules, which can sense glucose or other endogenous modulators of protein activity. In May 2020, AbbVie acquired Allergan plc, following the receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. In December 2020, Endo International plc acquired BioSpecifics Technologies Corp., which is a commercial-stage biopharmaceutical company. A list of Key Players Covered in the Hormone Replacement Therapy Market Are: Eli Lilly and Company, Pfizer, Inc., AbbVie, Inc., Novo Nordisk A/S, Merck KGaA, Mylan N.V., Bayer Healthcare, F. Hoffmann-La Roche Ltd., Teva Pharmaceuticals, Endo International, Sun Pharmaceutical Industries Ltd, Tolmar Pharmaceuticals, Inc., Novartis AG, Upsher-Smith Laboratories Inc., SottoPelle, Neuva Aesthetics, Ascend Therapeutics Want more insights? Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/3871 Hormone Replacement Therapy Market: Segmentation Based on Therapy Type: